Stock Analyst Note
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
We are holding steady to our fair value estimate for AbbVie following largely in-line first-quarter results. AbbVie continues to execute very well around the US Humira loss of exclusivity, which was a key factor in our moat rating increase to wide earlier in the year.